In Silico Analysis and Immunohistochemical Characterization of NaPi2b Protein Expression in Ovarian Carcinoma With Monoclonal Antibody Mx35

Soares, Iberê C.; Simões, Kleber; Souza, Jorge Estefano Santana de; Okamoto, Oswaldo Keith; Wakamatsu, Alda; Tuma, M. Carolina; Ritter, Gerd; Alves, Venâncio Avancini Ferreira

doi:10.1097/pai.0b013e318228e232

Cited by 8 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to the findings of Shyian et al, who describe staining of NaPi2b predominantly at the surface membrane of cancer cells in well differentiated serous and endometrioid ovarian cancer [21], we identified pattern C (both membrane and cytoplasm) as the most common pattern for the malignant tumors, represented in 61% of the tumors. For borderline samples pattern A was presented in 90% of the cases and the remaining tumors showed pattern C. In concordance with Soares et al, we identified pattern B, staining in all the membrane of all layers of cancer cells, as the least common pattern with fifteen malignant tumors presenting pattern B [7]. …”

Section: Discussionsupporting

confidence: 87%

“…Because of the protein function and results from previous studies it was expected to find NaPi2b located to cell membranes [3, 4, 6, 7]. When we evaluated the TMAs we identified differences in the staining pattern between the tumors (Fig.…”

Section: Resultsmentioning

confidence: 86%

“…The normal expression is in epithelial cells like type II pneumocytes, brush border membrane of small intestine and in the mammary gland [1, 2]. The protein is involved in actively transporting phosphate ions into the cell by a Na + co-transport [3–7]. Protein expression is further evident in female genital tract, endometrium, cervix and fallopian tube [8].…”

Section: Introductionmentioning

confidence: 99%

“…The results are described and correlated to clinical pathology. The number of samples included in previous expression pattern studies of NaPi2b in ovarian cancer range from n = 14–50 [4, 7, 9, 21], and our objective was to establish the antigen expression in a larger set of EOC samples.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b

et al. 2017

View full text Add to dashboard Cite

BackgroundTo characterize the expression of the membrane transporter NaPi2b and antigen targeted by the MX35 antibody in ovarian tumor samples. The current interest to develop monoclonal antibody based therapy of ovarian cancer by targeting NaPi2b emphasizes the need for detailed knowledge and characterization of the expression pattern of this protein. For the majority of patients with ovarian carcinoma the risk of being diagnosed in late stages with extensive loco-regional spread disease is substantial, which stresses the need to develop improved therapeutic agents.MethodsThe gene and protein expression of SLC34A2/NaPi2b were analyzed in ovarian carcinoma tissues by QPCR (n = 73) and immunohistochemistry (n = 136). The expression levels and antigen localization were established and compared to the tumor characteristics and clinical data.ResultsPositive staining for the target protein, NaPi2b was detected for 93% of the malignant samples, and we identified three separate distribution patterns of the antigen within the tumors, based on the localization of NaPi2b. There were differences in the staining intensity as well as the distribution pattern when comparing the tumor grade and histology, the mucinous tumors presented a significantly lower expression of both the targeted protein and its related gene.ConclusionOur study identified differences regarding the level of the antigen expression between tumor grade and histology. We have identified differences in the antigen localization between borderline tumors, type 1 and type 2 tumors, and suggest that a pathological evaluation of NaPi2b in the tumors would be helpful in order to know which patients that would benefit from this targeted therapy.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Resultsmentioning

confidence: 86%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b

et al. 2017

View full text Add to dashboard Cite

show abstract

“…High expression of NaPi2b has been found on the cell membranes of serous epithelial cancer cells, the most frequent histological subtype of ovarian cancer [15,16]. Clinical grade MX35 F(ab') 2 fragments (110 kDa) were provided by [BLIND].…”

Section: Monoclonal Antibodymentioning

confidence: 99%

Absorbed Doses and Risk Estimates of 211At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients

Cederkrantz

Andersson

Bernhardt

et al. 2015

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Inorganic phosphate transporters in cancer: Functions, molecular mechanisms and possible clinical applications

Lacerda-Abreu

Russo‐Abrahão

Monteiro

et al. 2018

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

In Silico Analysis and Immunohistochemical Characterization of NaPi2b Protein Expression in Ovarian Carcinoma With Monoclonal Antibody Mx35

Cited by 8 publications

References 26 publications

Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b

Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b

Absorbed Doses and Risk Estimates of 211At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients

Inorganic phosphate transporters in cancer: Functions, molecular mechanisms and possible clinical applications

Contact Info

Product

Resources

About